Quinoline Or Isoquinoline (including Hydrogenated) Patents (Class 544/363)
-
Patent number: 7449477Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.Type: GrantFiled: November 22, 2004Date of Patent: November 11, 2008Assignee: Eli Lilly and CompanyInventors: David Anthony Barda, Kenneth James Henry, Jr., Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Enrico Richett
-
Publication number: 20080275058Abstract: The present invention relates to compounds of N-substituted -1H-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of N-substituted-1H-quinoline-2,4-diones according to the present invention have excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors. Also, the compounds reverse a disruption of PPI by methamphetamine and don't show rotatod deficit in mice.Type: ApplicationFiled: November 23, 2005Publication date: November 6, 2008Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Churlmin Seong, Nosang Park, Jinil Choi, Wookyu Park, Jaeyang Kong, Chulmin Park
-
Publication number: 20080275040Abstract: This invention relates to novel quinoline compounds having pharmacological activity, to processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.Type: ApplicationFiled: August 26, 2004Publication date: November 6, 2008Applicant: GLAXO GROUP LIMITEDInventors: Christopher Norbert Johnson, Stephen Frederick Moss, Malcolm M. Tait, David R. Witty
-
Publication number: 20080275057Abstract: Novel substituted azole diones are provided that kill cells, suppress cell proliferation, suppress cell growth, abrogate the cell cycle G2 checkpoint and/or cause adaptation to G2 cell cycle arrest. Methods of making and using the invention compounds are provided. The invention provides substituted azole diones to treat cell proliferation disorders. The invention includes the use of substituted azole diones to selectively kill or suppress cancer cells without additional anti-cancer treatment. The invention includes the use of cell cycle G2-checkpoint-abrogating substituted azole diones to selectively sensitize cancer cells to DNA damaging reagents, treatments and/or other types of anti-cancer reagents.Type: ApplicationFiled: April 11, 2008Publication date: November 6, 2008Applicant: CanBas Co., Ltd.Inventors: Takumi Kawabe, Machiyo Ishigaki, Takuji Sato, Sayaka Yamamoto, Yoko Hasegawa
-
Publication number: 20080275056Abstract: The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 23, 2006Publication date: November 6, 2008Inventors: Alfonso De Dios, Cristina Garcia-Paredes, Beatriz Lopez Uralde Garmendia, Mary Margaret Mader, Mark Andrew Pobanz, Chuan Shih, Boyu Zhong
-
Publication number: 20080269243Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.Type: ApplicationFiled: March 19, 2008Publication date: October 30, 2008Applicant: Amgen Inc.Inventors: Holger Monenschein, G. Erich Wohlhieter, Qingping Zeng
-
Publication number: 20080269488Abstract: Provided are two novel crystalline forms of gatifloxacin, denominated form O and form V, and methods for their preparation.Type: ApplicationFiled: July 1, 2008Publication date: October 30, 2008Inventors: Valerie Niddam-Hildesheim, Shlomit Wizel, Greta Sterimbaum, Ehud Amir
-
Publication number: 20080267870Abstract: Racemic mixtures and enantiomerically pure forms of novel 1-[(2?-substituted)-piperazin-1?-yl]-isoquinolines are norepinephrine (NE) transporter (NET) inhibitor compounds. Compounds of the invention are considered therapeutic agents for central nervous system (CNS) diseases and disorders, without limitation, including neurodegeneration, anxiety, depression, attention deficit disorders, drug dependency, and post traumatic stress disorder. Examples of the chemical syntheses of the compounds of the invention are provided. The isoquinoline compounds of the invention competitively bind at NET at nanomolar concentrations. The isoquinoline agents of the invention bind selectively to NET over other competitive transporter targets and receptor binding sites, including those of serotonin and dopamine, amongst others. The chemical syntheses of the invention are suitable for labeling with radionuclide atoms.Type: ApplicationFiled: March 21, 2008Publication date: October 30, 2008Inventors: John M. Gerdes, David B. Bolstad, Michael R. Braden, August W. Barany
-
Patent number: 7442710Abstract: The present invention relates to compounds of general formula IA or IB wherein X1 and X2 are each independently N or C—R? and R1, R2,R3, R4, R5, and R6 are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The compounds can be used for the treatment of diseases related to the glycine transporter inhibitor, such as schizophrenia and Alzheimer's disease.Type: GrantFiled: January 24, 2006Date of Patent: October 28, 2008Assignee: Hoffman-La Roche Inc.Inventors: Synese Jolidon, Robert Narquizian, Roger David Norcross, Emmanuel Pinard
-
Publication number: 20080261964Abstract: The invention relates to substituted quinolones of formula (I) and to methods for their preparation as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, in particular against cytomegaloviruses.Type: ApplicationFiled: December 28, 2007Publication date: October 23, 2008Inventors: Rudolf Schohe-Loop, Holger Zimmermann, Kerstin Henninger, Dieter Lang, Kai Thede, Chantal Fuerstner, David Brueckner
-
Publication number: 20080261978Abstract: The invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: March 7, 2008Publication date: October 23, 2008Inventors: Michael P. Clark, Mark A. Lockwood, Florence F. Wagner, Michael G. Natchus
-
Publication number: 20080261987Abstract: Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.Type: ApplicationFiled: July 21, 2006Publication date: October 23, 2008Applicant: ChemoCentryx, Inc.Inventors: Andrew M.K. Pennell, James B. Aggen, J.J. Kim Wright, Subrabrata Sen, Brian E. McMaster, Daniel Joseph Dairaghi
-
Publication number: 20080262228Abstract: The present invention relates to novel metabolites of 5-Fluoro-8-{4-[4-(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline, which can be useful in treating CNS disorders. The present invention further relates to processes for their preparation, to pharmaceutical compositions comprising them, and to methods of using them.Type: ApplicationFiled: November 27, 2007Publication date: October 23, 2008Applicant: WyethInventors: Jianyao Wang, Alana Upthagrove, Lin Deng, Wayne Everett Childers, Zhongqi Shen, William Demaio, Robin D. Moore, Zeen Tong, Li Shen, Pixu Li, Michael K. May
-
Patent number: 7439244Abstract: Disclosed are quinoline compounds of formula (I) having pharmacological activity, processes for their preparation, compositions containing them, and methods for the treatment of CNS and other disorders.Type: GrantFiled: September 9, 2004Date of Patent: October 21, 2008Assignee: Glaxo Group LimitedInventors: Christopher Norbert Johnson, David R Witty
-
Patent number: 7439243Abstract: Disclosed are quinoline compounds of formula (I) having pharmacological activity, processes for their preparation, compositions containing them, and methods for the treatment of CNS and other disorders.Type: GrantFiled: September 23, 2004Date of Patent: October 21, 2008Assignee: Glaxo Group LimitedInventors: Christopher Norbert Johnson, Stephen Frederick Moss, David R Witty
-
Publication number: 20080255359Abstract: Disclosed is a novel, simplified and economic process for making 3-phenylsulphonyl quinolines with an amine group at position 8 of the quinoline ring system, including 3-phenylsulfonyl-8-piperazin-1-yl-quinoline in particular, in the absence of a palladium catalyst. Also disclosed is the crystallization of polymorphic forms of 3-phenylsulfonyl-8-piperazin-1-yl-quinoline.Type: ApplicationFiled: September 26, 2006Publication date: October 16, 2008Inventor: Charles Edward Wade
-
Publication number: 20080255116Abstract: Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of Formula (Ia) or (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a quaternary amine thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N-oxide form thereof, wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2 or 3; R2 is hydrogen; alkyl; hydroxy; mercapto; optionally substituted alkyloxy; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)amino wherein alkyl may optionally be substituted; Ar; Het or a radical of formula R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is zero, 1, 2, 3 or 4; X is a direct bond or CH2; R4 and R5 each independently are hydrogen, alkyl or benzyl; or R4 and R5 may be taken together including the N to which they areType: ApplicationFiled: July 31, 2006Publication date: October 16, 2008Inventors: Koenraad Jozef Lodewijk Marcel Andries, Anil Koul, Jerome Emile Georges Guillemont, Elisabeth Therese Jeanne Pasquier, David Francis Alain Lancois
-
Publication number: 20080254501Abstract: Chemical stain compounds containing a fluorophore and a reducible quenching unit are disclosed. The reducible quenching unit quenches the fluorophore while in its oxidized state. Upon reduction, the quenching properties of the quenching unit are diminished or eliminated. The chemical compounds can be used in a variety of applications, including the detection of bacterial cells, monitoring the electron transport chain function of bacterial cells, monitoring the oxidation state of non-biological systems, and assaying the effectiveness of antibacterial or antimicrobial agents.Type: ApplicationFiled: October 10, 2007Publication date: October 16, 2008Applicant: INVITROGEN CORPORATIONInventors: Ching-Ying Cheung, Diane R. Gray, Stephen T. Yue
-
Publication number: 20080255115Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using thiazolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiazolidinedione derivatives.Type: ApplicationFiled: August 24, 2007Publication date: October 16, 2008Inventors: Michael Gerard Darcy, Steven David Knight, Nicholas D. Adams, Stanley J. Schmidt
-
Publication number: 20080255145Abstract: The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.Type: ApplicationFiled: March 19, 2008Publication date: October 16, 2008Applicant: Amgen Inc.Inventors: Holger Monenschein, James T. Rider, Guomin Yao, Qingping Zeng
-
Patent number: 7432269Abstract: The invention relates to compounds of the general formula (I): to the process for preparing them, and to the use thereof as a therapeutic agent having the property of being selective ligands for the dopamine D3 receptor. These selective D3 ligands are useful as medicines in neuropsychiatry, in particular in the treatment of psychotic or depressive states, or in the treatment of motor disorders, such as dyskinesia or essential tremor. They are furthermore useful in the treatment of dependency on nicotine, cocaine, alcohol, opioids and for facilitating withdrawal in drug-dependent individuals.Type: GrantFiled: October 19, 2005Date of Patent: October 7, 2008Assignee: BioprojetInventors: Marc Capet, Denis Danvy, Nicolas Levoin, Marcel Morvan, Isabelle Berrebi-Bertrand, Thierry Calmels, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte
-
Patent number: 7432264Abstract: Provided are antibacterial biaryl compounds having micromolar MIC activity against Gram-negative and Gram-positive pathogens, including a methicillin-resistant S. aureus strain.Type: GrantFiled: August 9, 2004Date of Patent: October 7, 2008Assignee: Isis Pharmaceuticals, Inc.Inventors: Elizabeth Anne Jefferson, Eric E. Swayze, Punit P. Seth, Dale E. Robinson, Jr.
-
Patent number: 7432374Abstract: Inhibitors of MIF are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R1, R2, R3, R4, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.Type: GrantFiled: March 16, 2007Date of Patent: October 7, 2008Assignee: Avanir PharmaceuticalsInventors: Federico C. A. Gaeta, Andrew Baird, Jerry Anchin, Wenbin Ying, Robert Florkiewicz, Jagadish Sircar, Sunil Kumar K. C.
-
Patent number: 7429585Abstract: The present invention relates to compounds of the general formula IC wherein R2, R?, R?, R3, R6, X1 and X1? are as defined herein and pharmaceutically active acid addition salts thereof. Compounds of the invention are useful for the treatment of neurological and neuropsychiatric disorders.Type: GrantFiled: May 21, 2007Date of Patent: September 30, 2008Assignee: Hoffmann-La RocheInventors: Synese Jolidon, Robert Narquizian, Roger David Norcross, Emmanuel Pinard
-
Publication number: 20080234269Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.Type: ApplicationFiled: September 19, 2006Publication date: September 25, 2008Applicant: ASTRAZENECA ABInventors: James B. Campbell, Jeffrey S. Albert, Cristobal Alhambra, James Kang, Gerard M. Koether, Thomas R. Simpson, James Woods, Yan Li
-
Publication number: 20080234483Abstract: Fasudil-containing preparations that despite the us of a container excelling in the visibility of contents without particularly blocking of light, exhibit high stability against light; and a method of improving the stability of the preparations against light of storing the same. By regulating the pH value of aqueous solution of fasudil charged in a colorless transparent container to ?5.5, there can be provided fasudil-containing preparations excelling in stability against light; and can be provided a method of improving the stability of the aqueous solution of fasudil against light, or storing the same.Type: ApplicationFiled: March 4, 2005Publication date: September 25, 2008Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Takuji Maejima, Miki Ohshima
-
Publication number: 20080234272Abstract: The invention relates to novel piperazine derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, especially malaria.Type: ApplicationFiled: October 20, 2006Publication date: September 25, 2008Applicant: Actelion Pharmaceuticals Ltd.Inventors: Christoph Binkert, Christoph Boss, Olivier Corminboeuf, Corinna Grisostomi, Solange Meyer
-
Publication number: 20080234253Abstract: The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease, stroke, traumatic brain injury, and depression. This invention could also be used for research products including single agents or mixtures of agents to promote, proliferate, differentiate, or maintain neurons from stem or progenitor cells.Type: ApplicationFiled: September 19, 2006Publication date: September 25, 2008Applicant: NEURONASCENT, INC.Inventor: Judith Kelleher-Andersson
-
Publication number: 20080227792Abstract: Novel compounds of formula (I), pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase is beneficial.Type: ApplicationFiled: February 13, 2006Publication date: September 18, 2008Applicant: Novo Nordisk A/SInventors: Johannes Cornelis De Jong, Poul Jacobsen
-
Patent number: 7423153Abstract: Provided are novel crystalline forms of gatifloxacin denominated forms A, B, C, D, E1, F, G, H, I, and J, and methods for their preparation. Also provided are methods for making known crystalline forms of gatifloxacin, in particular forms omega and T2RP.Type: GrantFiled: May 12, 2003Date of Patent: September 9, 2008Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Valerie Niddam-Hildesheim, Shlomit Wizel, Greta Sterimbaum, Ehud Amir
-
Publication number: 20080214543Abstract: The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and the like. The present invention also provides a novel intermediate useful in producing the compound of the present invention.Type: ApplicationFiled: September 26, 2007Publication date: September 4, 2008Applicant: Astellas Pharma Inc.Inventors: Nobuaki Taniguchi, Masakazu Imamura, Masahiko Hayakawa, Kenichi Kawaguchi, Isao Kinoyama, Hiroyuki Kaizawa, Minoru Okada, Takashi Furutani
-
Publication number: 20080214455Abstract: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with hYAK3 activity.Type: ApplicationFiled: May 3, 2006Publication date: September 4, 2008Inventors: Kevin Duffy, Deping Chai, Mirela Colon, Duke M. Fitch, Sarah Rae King, Antony N. Shaw, Rosanna Tedesco, Kenneth Wiggall, Michael N. Zimmerman, Neil W. Johnson, Jiri Kasparec
-
Publication number: 20080214524Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.Type: ApplicationFiled: February 19, 2008Publication date: September 4, 2008Applicant: ABBOTT LABORATORIESInventors: CHIH-HUNG LEE, EROL K. BAYBURT, STANLEY DIDOMENICO, IRENE DRIZIN, ARTHUR R. GOMTSYAN, JOHN R. KOENIG, RICHARD J. PERNER, ROBERT G. SCHMIDT, SEAN C. TURNER, TAMMIE K. WHITE, GUO ZHU ZHENG
-
Publication number: 20080207617Abstract: An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R1, R2, and R3 represent H, OH, or optionally substituted alkoxy; R4 represents H; R5, R6, R7, and R8 represent H, Hal, alkyl or the like; and R9 represents, e.g., alkyl substituted by t-butyl or the like.Type: ApplicationFiled: October 29, 2003Publication date: August 28, 2008Applicant: KIRIN BEER KABUSHIKI KAISHAInventors: Atsushi Miwa, Tetsuya Yoshino, Mineo Kurokawa, Hisamaru Hirai, Naoko Hirai
-
Publication number: 20080199875Abstract: Embodiments of the present invention provide methods and nucleic acid reporter molecules for the detection of nucleic acid in a sample. The nucleic acid reporter molecule comprises two unsymmetrical cyanine monomer moieties, which may be the same or different, that are covalently attached by a linker comprising at least one aromatic, heteroaromatic, cyclic or heterocyclic moiety comprising 3-20 non-hydrogen atoms selected from the group consisting of O, N, S, P and C. The linker may be rigid, relatively flexible or some degree thereof. The unsymmetrical cyanine monomer moieties comprise a substituted or unsubstituted benzazolium moiety and a substituted or unsubstituted pyridinium or quinolinium moiety that is connected by a methine bridge that is monomethine, trimethine or pentamethine. The linkers form the cyanine dimer compounds by attaching to the pyridinium or quinolinium moiety of the monomer moieties.Type: ApplicationFiled: April 7, 2008Publication date: August 21, 2008Applicant: INVITROGEN CORPORATIONInventors: Stephen Yue, Ching-Ying Cheung
-
Patent number: 7414047Abstract: Substituted piperazinyl and diazepanyl benzamides and benzthioamides of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.Type: GrantFiled: October 21, 2003Date of Patent: August 19, 2008Assignee: Janssen Pharmaceutica N.V.Inventors: Richard L. Apodaca, Jill A. Jablonowski, Kiev S. Ly, Chandravadan R. Shah, Devin M. Swanson, Wei Xiao
-
Patent number: 7411067Abstract: Provided are two novel crystalline forms of gatifloxacin, denominated form O and form V, and methods for their preparation.Type: GrantFiled: June 16, 2003Date of Patent: August 12, 2008Assignee: Teva Pharmaceutical Industries LtdInventors: Valerie Niddam-Hildesheim, Shlomit Wizel, Greta Sterimbaum, Ehud Amir
-
Publication number: 20080188462Abstract: This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQR and CQS malaria parasites. RCQs are hybrid molecules, which include an antimalarial quinoline analog (such as chloroquine) moiety and a CQR reversal moiety. Exemplary RCQ chemical structures are provided. Also provided are pharmaceutical compositions including the disclosed RCQ compounds, and methods of using such compounds and compositions for the treatment of malaria and inhibition of CQR or CQS Plasmodium sp. (such as P. falciparum).Type: ApplicationFiled: December 12, 2005Publication date: August 7, 2008Inventors: David H. Peyton, Steven Burgess
-
Publication number: 20080188658Abstract: Provided is a method for making (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolenecarboxylic acid, commonly known as gatifloxacin, in high purity, in a suspension in a dipolar aprotic solvent.Type: ApplicationFiled: April 2, 2008Publication date: August 7, 2008Inventors: Valerie Niddam-Hildesheim, Ben-Zion Dolitzky, Gideon Pilarski, Greta Sterimbaum
-
Publication number: 20080188467Abstract: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.Type: ApplicationFiled: February 1, 2007Publication date: August 7, 2008Inventors: Norman C.W. Wong, Joseph E.L. Tucker, Henrik C. Hansen, Fabrizio S. Chiacchia, David McCaffrey
-
Publication number: 20080188655Abstract: The present invention relates to a monomer with anti-microbial characteristics, a polymeric compound with anti-microbial characteristics using the same, and manufacturing methods thereof, and more particularly, to an antimicrobial monomer comprising a saturated or unsaturated hydrocarbon having a polymerizable functional group within its structure. Also, the present invention provides a polymeric compound using the above antimicrobial monomer, a manufacturing method thereof, and a polymeric resin composition. The compounds according to the present invention have durable antimicrobial activity and high heat resistance, they do not give rise to toxicity when added to conventional resins by not eluting the antimicrobial compounds, and they do not have an effect on the properties of molded products.Type: ApplicationFiled: March 31, 2008Publication date: August 7, 2008Applicant: Micro Science Tech Co., Ltd.Inventors: Woong-Sig Moon, Jae-Chul Kim, Kyoo-Hyun Chung, Ki-Oh Kong, Jung-Hwa Hwang
-
Publication number: 20080182856Abstract: The present invention provides novel crystalline forms of aripiprazole and aripiprazole hydrochloride, processes for their preparation and pharmaceutical compositions containing them.Type: ApplicationFiled: October 10, 2007Publication date: July 31, 2008Applicant: HETERO DRUGS LIMITEDInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy, Kesireddy Subash Chander Reddy
-
Publication number: 20080182988Abstract: The present invention provides novel crystalline forms of aripiprazole and processes for their preparation.Type: ApplicationFiled: October 10, 2007Publication date: July 31, 2008Applicant: HETERO DRUGS LIMITEDInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Murallidhara Reddy, Kesireddy Subash Chander Reddy
-
Publication number: 20080182855Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of a bacterial disease including a mycobacterial disease, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of bacterial diseases and a process for preparing the claimed compounds.Type: ApplicationFiled: July 26, 2006Publication date: July 31, 2008Inventors: Jerome Emile Georges Guillemont, David Francis Alain Lancois, Elisabeth Therese Jeanne Pasquier, Koenraad Jozef Lodewijk Andries, Anil Koul
-
Patent number: 7405217Abstract: This invention relates to N-aroyl cyclic amino derivatives and their use as pharmaceuticals.Type: GrantFiled: November 9, 2006Date of Patent: July 29, 2008Assignee: SmithKline Beecham p.l.c.Inventors: Clive Leslie Branch, Christopher Norbert Johnson, David John Nash, Geoffrey Stemp
-
Patent number: 7402583Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt thereof, a process for t he preparation of a compound of Formula (1a) and pharmaceutical compositions of a compound of Formula (1a).Type: GrantFiled: March 14, 2006Date of Patent: July 22, 2008Assignee: AstrZenca ABInventors: Francis Thomas Boyle, Keith Hopkinson Gibson, Kevin Michael Foote
-
Publication number: 20080167320Abstract: Compounds of the general formula (I) below: are provided along with a process for preparing them, and these compounds may be used as therapeutic agents, e.g., for prevention and/or treatment of a neuropsychiatric illness or any illness involving the dopamine D3 receptor.Type: ApplicationFiled: March 7, 2008Publication date: July 10, 2008Inventors: Marc Capet, Denis Danvy, Nicolas Levoin, Marcel Morvan, Isabelle Berrebi-Bertrand, Thierry Calmels, Philippe Robert, Jean-Charles Schwartz, Jeanne-Marie Lecomte
-
Patent number: 7396834Abstract: Compounds of general formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.Type: GrantFiled: November 5, 2003Date of Patent: July 8, 2008Assignee: AstraZeneca ABInventors: William Brown, Andrew Griffin, Niklas Plobeck, Christopher Walpole
-
Publication number: 20080161297Abstract: Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.Type: ApplicationFiled: September 18, 2007Publication date: July 3, 2008Inventors: Todd Bosanac, John David Ginn, Eugene Richard Hickey, Thomas Martin Kirrane, Weimin Liu, Anthony S. Prokopowicz, Sabine K. Schlyer, Cheng-Kon Shih, Roger John Snow, Michael Robert Turner, Frank Wu, Erick Richard Young
-
Publication number: 20080153799Abstract: The present invention relates to novel compounds which are JAK3 Kinase inhibitors, methods for their preparation and pharmaceutical compositions comprising them.Type: ApplicationFiled: February 7, 2005Publication date: June 26, 2008Applicant: ASTRAZENECA ABInventors: David Laurent, Jorgen Gustafsson, Karolina Lawitz, Tesfaledet Mussie, Antonios Nikitidis